MyFinsight
Home
Blog
About
Contact
Download
Download image
something is missing
$19,207K
Net cash provided by
financing activities
$7,192K
Canceled cashflow
$12,015K
Increase (decrease) in
cash and cash...
-$51,450K
Canceled cashflow
$7,192K
Research fees and grants
receivable
-$13,103K
Stock-based compensation
$12,013K
Depreciation of property and
equipment
$5,918K
something is missing
$2,791K
Other
-$2,377K
Amortization of operating
lease right-of-use...
$1,817K
Proceeds from marketable
securities
$143,802K
Receipt of grant funding
$1,361K
Proceeds from long-term
liabilities and other
-$12,015K
Net cash used in
operating activities
-$33,523K
Net cash provided by
(used in) investing...
-$25,081K
Canceled cashflow
$38,019K
Canceled cashflow
$145,163K
Effect of exchange rate
changes on cash and cash...
-$38K
Net loss
-$43,165K
Purchase of marketable
securities
$166,308K
Accounts payable and
accrued liabilities
-$9,406K
Deferred revenue
-$8,033K
Income taxes payable
-$4,970K
Deferred grant income
$2,356K
Amortization of intangible
assets
-$1,871K
Other assets
$1,741K
Purchases of property and
equipment
$3,831K
Long-term investments and
other assets
$105K
Back
Back
Cash Flow
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)
source: myfinsight.com